Tirzepatide

Tirzepatide is a synthetic peptide designed to activate both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors. These incretin receptors are involved in metabolic signaling after nutrient intake. Research around tirzepatide focuses on how dual receptor activity may influence glucose handling, insulin secretion, appetite regulation, gastric emptying, body-weight physiology, and broader metabolic markers.

Incretin receptors help coordinate the body's response to food intake. GLP-1 receptor activation is associated with glucose-dependent insulin secretion, reduced glucagon signaling when glucose is elevated, slower gastric emptying, and central appetite signaling. GIP receptor activation is involved in insulin secretion and adipose-tissue signaling. Tirzepatide research examines whether coordinated GIP and GLP-1 receptor activation produces additive or distinct metabolic effects compared with GLP-1-only signaling.

• Glucose-dependent insulin secretion and post-meal glucose regulation.
• Changes in appetite signaling, satiety pathways, and energy intake behavior.
• Effects on body-weight physiology, adipose biology, and metabolic biomarkers.
• Comparative incretin biology between dual agonism and single-receptor GLP-1 activity.
• Cardiometabolic markers such as lipids, blood pressure, inflammation, and liver-related metabolic endpoints.

• Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
• Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 2021.
• Nauck MA and Meier JJ. Incretin hormones: their role in health and disease. Diabetes, Obesity and Metabolism, 2018.